Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin effects on hormonal glucose regulation in T1D
NCT04035031Phase 3Completed
- Sponsor
- Insel Gruppe
- Start
- Jan 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Insel Gruppe. Primary endpoint: Area under the curve for glucagon-like peptide I in oral glucose tolerance test clamp. Started Jan 2020; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04035031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04035031.